Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 130.26% | -449.17% | 940.31% | -109.30% | 227.09% |
| Total Depreciation and Amortization | 32.36% | -37.50% | -1.38% | -0.26% | 28.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.39% | -76.65% | -38.18% | 415.98% | -145.14% |
| Change in Net Operating Assets | -171.25% | 726.75% | -271.56% | 163.75% | -1,337.72% |
| Cash from Operations | 68.66% | -80.39% | -5.57% | 71.95% | 2.32% |
| Capital Expenditure | -14.32% | -9.37% | 0.64% | 18.04% | -3.61% |
| Sale of Property, Plant, and Equipment | 1,899.22% | 253.65% | -- | -100.00% | 20,951.43% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 1,900.88% | -84.02% | 755.56% | -98.82% | 181.84% |
| Other Investing Activities | -266.21% | 93.73% | -2,081.83% | 60.78% | -222.07% |
| Cash from Investing | -48.89% | 75.20% | -356.85% | -42.02% | -77.96% |
| Total Debt Issued | -- | -- | -100.00% | 86.60% | 567.72% |
| Total Debt Repaid | 86.82% | -766.02% | 96.77% | -66.70% | 20.55% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -3.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1,582.85% | 94.21% | -1,522.96% | 94.08% | -1,474.33% |
| Other Financing Activities | 58.41% | -28.52% | 15.65% | -120.53% | 53.27% |
| Cash from Financing | -129.23% | 60.45% | -1,437.05% | 94.54% | 24.86% |
| Foreign Exchange rate Adjustments | 469.55% | -95.19% | 60.71% | 637.51% | 73.51% |
| Miscellaneous Cash Flow Adjustments | 198.44% | -- | -- | -- | -- |
| Net Change in Cash | -120.52% | -121.52% | -107.66% | 1,024.77% | 66.02% |